SeaCrest Wealth Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

SeaCrest Wealth Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-800	Closed	-$14K	–	2397
2018 Q3	$14K	Buy	+800	New	+$13.7K	﹤0.01%	1527

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

SeaCrest Wealth Management's ECYT Position: Q4 2018 in Review

SeaCrest Wealth Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 800 shares — an estimated $14K sold.

SeaCrest Wealth Management first reported a position in ECYT in Q3 2018 and held it in 1 quarter. The position peaked at $14K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

SeaCrest Wealth Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
SeaCrest Wealth Management sold 800 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $14K.
SeaCrest Wealth Management first reported a position in Endocyte, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
SeaCrest Wealth Management's Endocyte, Inc. Common Stock position peaked at $14K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on SeaCrest Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.